Given that the antibodies and small molecule inhibitors against EGFR exerted therapeutic effects on NSCLC patients, therapeutic strategies of EGFR inhibition may enable conceivable benefits in PDAC treatment, and have been developed and tested in pre-clinical and clinical studies. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.